Aspira Women’s Health expands collaboration with Bioreference

Aspira Women’s Health (AWH) announced the expansion of its co-marketing and distribution collaboration with BioReference Health, a wholly-owned subsidiary of OPKO Health. (OPK), a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Under the terms of the expanded agreement, Aspira and BioReference will join forces to market Aspira’s complete OvaSuite portfolio, including OvaWatch(R) and Ova1Plus, to BioReference women’s healthcare provider clients. BioReference and Aspira have co-marketed and distributed Ova1Plus since 2022. The approval of OvaWatch by the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) in early October paved the way for the expanded relationship by making it available to the 15+ million women in New York and New Jersey.